Ginkgo Bioworks Holdings, Inc. (NYSE:DNA – Get Rating) shares were down 3.8% during trading on Monday following insider selling activity. The stock traded as low as $1.25 and last traded at $1.25. Approximately 8,193,812 shares changed hands during mid-day trading, a decline of 58% from the average daily volume of 19,583,656 shares. The stock had previously closed at $1.30.

Specifically,  insider Reshma P. Shetty sold 151,769 shares of the business’s stock in a transaction dated Tuesday, February 7th. The shares were sold at an average price of $1.96, for a total value of $297,467.24. Following the completion of the sale, the insider now owns 14,235,318 shares of the company’s stock, valued at approximately $27,901,223.28. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. In related news, insider Reshma P. Shetty sold 151,769 shares of the company’s stock in a transaction that occurred on Tuesday, February 7th. The stock was sold at an average price of $1.96, for a total transaction of $297,467.24. Following the sale, the insider now directly owns 14,235,318 shares of the company’s stock, valued at approximately $27,901,223.28. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, insider Reshma P. Shetty sold 162,193 shares of the business’s stock in a transaction on Thursday, January 19th. The shares were sold at an average price of $1.71, for a total transaction of $277,350.03. Following the sale, the insider now owns 16,142,867 shares of the company’s stock, valued at approximately $27,604,302.57. The disclosure for this sale can be found here. In the last three months, insiders sold 2,529,300 shares of company stock worth $4,417,316. 17.47% of the stock is currently owned by insiders.

A number of research firms have commented on DNA. Raymond James dropped their price target on shares of Ginkgo Bioworks from $6.00 to $5.00 and set an “outperform” rating on the stock in a research report on Friday, March 3rd. BTIG Research decreased their price target on Ginkgo Bioworks from $4.00 to $3.00 in a research note on Sunday, March 5th. One research analyst  has rated the stock with a sell rating, one  has issued  a hold rating and three have assigned  a buy rating to the company’s stock. Based on data from MarketBeat, Ginkgo Bioworks presently has an average rating of “Hold” and a consensus price target of $4.39.

The stock’s fifty day moving average is $1.41 and its two-hundred day moving average is $1.88. The stock has a market capitalization of $2.59 billion, a P/E ratio of -0.97 and a beta of 0.89.

A number of institutional investors have recently bought and sold shares of DNA. ARK Investment Management LLC lifted its position in shares of  Ginkgo Bioworks by 14.1% in the 1st quarter. ARK Investment Management LLC now owns 164,756,985 shares of the company’s stock valued at $219,127,000 after acquiring an additional 20,372,918 shares in the last quarter.  Raymond James & Associates grew its holdings in shares of  Ginkgo Bioworks by 4.8% during the first quarter. Raymond James & Associates now owns 174,722 shares of the company’s stock valued at $232,000 after buying an additional 8,044 shares in the last quarter.  626 Financial LLC boosted its position in  Ginkgo Bioworks by 52.7% during the 1st quarter. 626 Financial LLC now owns 70,762 shares of the company’s stock worth $94,000 after acquiring an additional 24,415 shares during the period.  Green Alpha Advisors LLC acquired a new stake in  Ginkgo Bioworks during the 1st quarter worth about $120,000.  Finally, Polianta Ltd increased its stake in  Ginkgo Bioworks by 108.2% in the 1st quarter. Polianta Ltd now owns 732,300 shares of the company’s stock valued at $973,000 after buying an additional 380,600 shares during the period. Hedge funds and other institutional investors own  61.83% of the company’s stock.

Ginkgo Bioworks Holdings, Inc, together with its subsidiaries, develops platform for cell programming. Its platform is used to program cells to enable biological production of products, such as novel therapeutics, food ingredients, and chemicals derived from petroleum. The company serves various end markets, including specialty chemicals, agriculture, food, consumer products, and pharmaceuticals.

Receive News & Ratings for Ginkgo Bioworks Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ginkgo Bioworks and related companies with MarketBeat.com's FREE daily email newsletter.